A genuine collaborative model applied to medicinal research
At Pherecydes Pharma, working hand in hand with academic partners or private companies is not an empty word.
Thanks to this true culture of scientific collaboration, the company's products have been developed rapidly.
Rather than reinventing the wheel, the company joins forces with research units that master the skills, tools or know-how that Pherecydes Pharma has not developed internally yet.
Our latest collaboration
July 16, 2019, Pherecydes Pharma and BIOASTER announced the signing of a collaboration agreement In order to explore the use of phage therapy to treat complicated urinary tract infections.
The pooling of the expertise of BIOASTER in preclinical models and the experience of Pherecydes Pharma in phagotherapy led to the launch of the PhagUTI project.
Created in 2012, following the French initiative of Technological Research Institutes (TRI), BIOASTER is a non-for-profit foundation developing a unique technological and innovative model to support the latest challenges in microbiology.
In particular, BIOASTER uses and develops high value technological innovations that accelerate development of medical solutions for populations and personalized medicine.
The aim of BIOASTER is to bring together academic, industry and its capacities and specific knowledge to develop and execute high impact collaborative projects requiring industry compatible innovative technologies.